The CHMP positive opinion is a strong catalyst for AZN, reinforcing Enhertu's leadership in the ADC space and expanding its label in a major market. Monitor for formal EC approval (typically within 2-3 months of CHMP opinion) and subsequent launch. The ongoing EU reviews for DESTINY-Breast09 and DESTINY-Breast05 provide additional near-term pipeline catalysts.
Price Chart
Executive Summary
AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP opinion recommending EU approval as a tumor-agnostic monotherapy for previously treated HER2-positive (IHC 3+) metastatic solid tumors. If approved, it would be the first HER2-directed therapy and ADC with a tumor-agnostic indication in the EU, based on Phase II data showing clinically meaningful responses across multiple tumor types. This expands Enhertu's addressable market in the EU beyond its current approvals in breast, lung, and gastric cancers.
Key Facts
- CHMP recommended Enhertu for EU approval as monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior treatment and have no satisfactory treatment options.
- If approved, Enhertu would become the first HER2-directed therapy and antibody drug conjugate to receive a tumor-agnostic indication in the EU.
- The recommendation is based on data from three Phase II trials: DESTINY-PanTumor02 (ORR 51.4%, median DOR 14.2 months in IHC 3+ tumors, n=111), DESTINY-Lung01 (ORR 52.9%, median DOR 6.9 months in IHC 3+ NSCLC, n=17), and DESTINY-CRC02 (ORR 46.9%, median DOR 5.5 months in IHC 3+ colorectal cancer, n=64).
- Enhertu already has a tumor-agnostic indication in the US and other countries based on the DESTINY-PanTumor02 trial.
- Additional EU regulatory submissions are under review for Enhertu in combination with pertuzumab for 1st-line HER2+ breast cancer (DESTINY-Breast09) and for HER2+ breast cancer with residual invasive disease after neoadjuvant treatment (DESTINY-Breast05).
Financial Impact
Expands Enhertu's addressable EU market to include all HER2-positive (IHC 3+) solid tumors, potentially adding hundreds of millions in annual revenue. Enhertu is already approved in >95 countries for breast cancer and >75 for NSCLC; this tumor-agnostic label opens a new patient population across biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and other tumors.
Risk Factors
- Final European Commission approval is not guaranteed and could be delayed or conditional.
- Tumor-agnostic approval is based on Phase II data; confirmatory trials may be required for full approval.
- Competition from other HER2-directed ADCs and therapies could limit market share.
- Enhertu's safety profile includes interstitial lung disease risk, which could impact real-world adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005306 |
| Document: 0001654954-26-005306-index-headers.html | 0001654954-26-005306 |
| Document: 0001654954-26-005306-index.html | 0001654954-26-005306 |
| Document: 0001654954-26-005306.txt | 0001654954-26-005306 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access